Cosciens Biopharma
Logotype for Cosciens Biopharma Inc

Cosciens Biopharma (CSCI) investor relations material

Cosciens Biopharma Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cosciens Biopharma Inc
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • Q3 revenue rose 70% YoY to $2.516M, while consolidated net loss widened to $3.445M, primarily reflecting a $2.044M PGX impairment and acquisition-related costs.

  • Nualtis was acquired on September 10, adding oral thin-film development and manufacturing; 20 days of its results were included in Q3.

  • 9M net income was $7.113M, including $10.940M from discontinued operations; continuing operations recorded a $3.827M loss.

Financial highlights

  • Q3 revenue was $2.516M vs. $1.476M YoY; gross profit rose to $1.378M from $0.623M.

  • 9M revenue was $7.547M vs. $5.280M; gross profit was $3.909M vs. $1.745M.

  • Q3 consolidated net loss was $3.445M, or $3.45 per share, vs. $1.819M and $1.72 per share; $1.1M of acquisition and financing-related professional fees contributed to higher SG&A.

  • 9M consolidated net income was $7.113M vs. a $8.175M loss in 2025; discontinued operations contributed $10.940M of net income.

  • Cash and cash equivalents were $9.207M at September 30, 2026, vs. $7.307M at December 31, 2025.

Outlook and guidance

  • Management expects existing cash and projected operating cash flows to cover liabilities for at least 12 months, assuming debenture conversion; forecasts remain exposed to uncertain revenue and cash generation.

  • Liquidity forecasts assume required shareholder and TSX approvals, sufficient operating cash flows and timely payment of $6.0M deferred acquisition consideration; the debenture offering was expected to remain open through November 30, 2026.

  • Cost and cash-conservation measures include lower R&D spending and capex, operational restructuring, and manufacturing and procurement reviews to improve margins.

  • Development priorities include oat extraction improvements for avenanthramides and oat beta glucan, plus work on oat oil, protein and peptides; Rizatriptan OTF was expected to launch in Q4 2026.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Cosciens Biopharma earnings date

Logotype for Cosciens Biopharma Inc
Q4 202625 Mar, 2027
Cosciens Biopharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Cosciens Biopharma earnings date

Logotype for Cosciens Biopharma Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Cosciens Biopharma Inc is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. The company targets therapeutic areas including oncology, immunology, and central nervous system disorders. It employs proprietary drug discovery platforms and engages in clinical development activities. The company is headquartered in Suzhou, China, and its shares are listed on the SSE STAR Market.